» Articles » PMID: 31473903

The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV

Overview
Publisher Current Science
Date 2019 Sep 2
PMID 31473903
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: People infected with HIV through injection drug use are more likely to experience progression to AIDS, death due to AIDS, and all-cause mortality even when controlling for access to care and antiretroviral therapy. While high-risk behavior and concurrent infections most certainly are contributors, chronic immune activation, downstream metabolic comorbidities may play an important role.

Recent Findings: Altered intestinal integrity plays a major role in HIV-related immune activation and microbial translocation markers are heightened in active heroin users. Additionally, greater injection frequency drives systemic inflammation and is associated with HIV viral rebound. Finally, important systemic inflammation markers have been linked with frailty and mortality in people who inject drugs with and without concurrent HIV infection. Heroin use may work synergistically with HIV infection to cause greater immune activation than either factor alone. Further research is needed to understand the impact on downstream metabolic comorbidities including cardiovascular disease. Medication-assisted treatment for opioid use disorder with methadone or buprenorphine may ameliorate some of this risk; however, there is presently limited research in humans, including in non-HIV populations, describing changes in immune activation on these treatments which is of paramount importance for those with HIV infection.

Citing Articles

How likely is unmeasured confounding to explain meta-analysis-derived associations between alcohol, other substances, and mood-related conditions with HIV risk behaviors?.

Manandhar-Sasaki P, Ban K, Richard E, Braithwaite R, Caniglia E BMC Med Res Methodol. 2025; 25(1):62.

PMID: 40055588 PMC: 11887180. DOI: 10.1186/s12874-025-02490-9.


A Perfect Storm: The Convergence of Aging, Human Immunodeficiency Virus Infection, and Inflammasome Dysregulation.

Thirugnanam S, Rout N Curr Issues Mol Biol. 2024; 46(5):4768-4786.

PMID: 38785555 PMC: 11119826. DOI: 10.3390/cimb46050287.


Changes in atherosclerotic cardiovascular disease risk over time among people living with HIV.

Chen W, Petoumenos K, Somia A, Edmiston N, Chaiwarith R, Woolley I J Antimicrob Chemother. 2024; 79(4):897-902.

PMID: 38416697 PMC: 10984948. DOI: 10.1093/jac/dkae049.


Tobacco Smoking and Pack-Years Are Associated With Frailty Among People With HIV.

Ruderman S, Odden M, Webel A, Fitzpatrick A, Crane P, Nance R J Acquir Immune Defic Syndr. 2023; 94(2):135-142.

PMID: 37368939 PMC: 10527292. DOI: 10.1097/QAI.0000000000003242.


HIV and Drug Use: A Tale of Synergy in Pulmonary Vascular Disease Development.

Cook C, Craddock V, Ram A, Abraham A, Dhillon N Compr Physiol. 2023; 13(3):4659-4683.

PMID: 37358518 PMC: 10693986. DOI: 10.1002/cphy.c210049.


References
1.
Boland J, Foulds G, Ahmedzai S, Pockley A . A preliminary evaluation of the effects of opioids on innate and adaptive human in vitro immune function. BMJ Support Palliat Care. 2014; 4(4):357-67. DOI: 10.1136/bmjspcare-2013-000573. View

2.
Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

3.
. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

4.
Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

5.
Ladak F, Socias E, Nolan S, Dong H, Kerr T, Wood E . Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting. Antivir Ther. 2018; 24(1):19-25. PMC: 6455806. DOI: 10.3851/IMP3265. View